Stopped: This study was cancelled with no patients
This study is designed to assess the safety and exploratory efficacy of using HSC835 in patients with Inherited Metabolic Disorders (IMD) undergoing stem cell transplantation.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence of infusional toxicities
Timeframe: 48 hours
Incidence of neutrophil recovery
Timeframe: 42 days
Incidence of graft failure
Timeframe: 42 days